{"pmid":32353252,"pmcid":"PMC7189862","title":"Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza.","text":["Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza.","The coronavirus disease 2019 (COVID-19) pandemic, caused by the SARS-CoV-2 virus, has highlighted the need for antiviral approaches that can target emerging viruses with no effective vaccines or pharmaceuticals. Here, we demonstrate a CRISPR-Cas13-based strategy, PAC-MAN (prophylactic antiviral CRISPR in human cells), for viral inhibition that can effectively degrade RNA from SARS-CoV-2 sequences and live influenza A virus (IAV) in human lung epithelial cells. We designed and screened CRISPR RNAs (crRNAs) targeting conserved viral regions and identified functional crRNAs targeting SARS-CoV-2. This approach effectively reduced H1N1 IAV load in respiratory epithelial cells. Our bioinformatic analysis showed that a group of only six crRNAs can target more than 90% of all coronaviruses. With the development of a safe and effective system for respiratory tract delivery, PAC-MAN has the potential to become an important pan-coronavirus inhibition strategy.","Cell","Abbott, Timothy R","Dhamdhere, Girija","Liu, Yanxia","Lin, Xueqiu","Goudy, Laine","Zeng, Leiping","Chemparathy, Augustine","Chmura, Stephen","Heaton, Nicholas S","Debs, Robert","Pande, Tara","Endy, Drew","La Russa, Marie F","Lewis, David B","Qi, Lei S","32353252"],"abstract":["The coronavirus disease 2019 (COVID-19) pandemic, caused by the SARS-CoV-2 virus, has highlighted the need for antiviral approaches that can target emerging viruses with no effective vaccines or pharmaceuticals. Here, we demonstrate a CRISPR-Cas13-based strategy, PAC-MAN (prophylactic antiviral CRISPR in human cells), for viral inhibition that can effectively degrade RNA from SARS-CoV-2 sequences and live influenza A virus (IAV) in human lung epithelial cells. We designed and screened CRISPR RNAs (crRNAs) targeting conserved viral regions and identified functional crRNAs targeting SARS-CoV-2. This approach effectively reduced H1N1 IAV load in respiratory epithelial cells. Our bioinformatic analysis showed that a group of only six crRNAs can target more than 90% of all coronaviruses. With the development of a safe and effective system for respiratory tract delivery, PAC-MAN has the potential to become an important pan-coronavirus inhibition strategy."],"journal":"Cell","authors":["Abbott, Timothy R","Dhamdhere, Girija","Liu, Yanxia","Lin, Xueqiu","Goudy, Laine","Zeng, Leiping","Chemparathy, Augustine","Chmura, Stephen","Heaton, Nicholas S","Debs, Robert","Pande, Tara","Endy, Drew","La Russa, Marie F","Lewis, David B","Qi, Lei S"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32353252","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.cell.2020.04.020","keywords":["2019-ncov","covid-19","crispr","cas13","iav","rdrp","sars-cov-2","antiviral","influenza","nucleocapsid"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495601606656,"score":9.490897,"similar":[{"pmid":32349121,"title":"Massively multiplexed nucleic acid detection using Cas13.","text":["Massively multiplexed nucleic acid detection using Cas13.","The overwhelming majority of globally circulating pathogens go undetected, undermining patient care and hindering outbreak preparedness and response. To enable routine surveillance and comprehensive diagnostic applications, there is a need for detection technologies that can scale to test many samples(1-3) while simultaneously testing for many pathogens(4-6). Here, we develop Combinatorial Arrayed Reactions for Multiplexed Evaluation of Nucleic acids (CARMEN), a platform for scalable, multiplexed pathogen detection. In the CARMEN platform, nanoliter droplets containing CRISPR-based nucleic acid detection reagents(7) self-organize in a microwell array(8) to pair with droplets of amplified samples, testing each sample against each CRISPR RNA (crRNA) in replicate. The combination of CARMEN and Cas13 detection (CARMEN-Cas13) enables robust testing of >4,500 crRNA-target pairs on a single array. Using CARMEN-Cas13, we developed a multiplexed assay that simultaneously differentiates all 169 human-associated viruses with >/=10 published genome sequences and rapidly incorporated an additional crRNA to detect the causative agent of the 2020 COVID-19 pandemic. CARMEN-Cas13 further enables comprehensive subtyping of influenza A strains and multiplexed identification of dozens of HIV drug-resistance mutations. CARMEN's intrinsic multiplexing and throughput capabilities make it practical to scale, as miniaturization decreases reagent cost per test >300-fold. Scalable, highly-multiplexed CRISPR-based nucleic acid detection shifts diagnostic and surveillance efforts from targeted testing of high-priority samples to comprehensive testing of large sample sets, greatly benefiting patients and public health(9-11).","Nature","Ackerman, Cheri M","Myhrvold, Cameron","Thakku, Sri Gowtham","Freije, Catherine A","Metsky, Hayden C","Yang, David K","Ye, Simon H","Boehm, Chloe K","Kosoko-Thoroddsen, Tinna-Solveig F","Kehe, Jared","Nguyen, Tien G","Carter, Amber","Kulesa, Anthony","Barnes, John R","Dugan, Vivien G","Hung, Deborah T","Blainey, Paul C","Sabeti, Pardis C","32349121"],"abstract":["The overwhelming majority of globally circulating pathogens go undetected, undermining patient care and hindering outbreak preparedness and response. To enable routine surveillance and comprehensive diagnostic applications, there is a need for detection technologies that can scale to test many samples(1-3) while simultaneously testing for many pathogens(4-6). Here, we develop Combinatorial Arrayed Reactions for Multiplexed Evaluation of Nucleic acids (CARMEN), a platform for scalable, multiplexed pathogen detection. In the CARMEN platform, nanoliter droplets containing CRISPR-based nucleic acid detection reagents(7) self-organize in a microwell array(8) to pair with droplets of amplified samples, testing each sample against each CRISPR RNA (crRNA) in replicate. The combination of CARMEN and Cas13 detection (CARMEN-Cas13) enables robust testing of >4,500 crRNA-target pairs on a single array. Using CARMEN-Cas13, we developed a multiplexed assay that simultaneously differentiates all 169 human-associated viruses with >/=10 published genome sequences and rapidly incorporated an additional crRNA to detect the causative agent of the 2020 COVID-19 pandemic. CARMEN-Cas13 further enables comprehensive subtyping of influenza A strains and multiplexed identification of dozens of HIV drug-resistance mutations. CARMEN's intrinsic multiplexing and throughput capabilities make it practical to scale, as miniaturization decreases reagent cost per test >300-fold. Scalable, highly-multiplexed CRISPR-based nucleic acid detection shifts diagnostic and surveillance efforts from targeted testing of high-priority samples to comprehensive testing of large sample sets, greatly benefiting patients and public health(9-11)."],"journal":"Nature","authors":["Ackerman, Cheri M","Myhrvold, Cameron","Thakku, Sri Gowtham","Freije, Catherine A","Metsky, Hayden C","Yang, David K","Ye, Simon H","Boehm, Chloe K","Kosoko-Thoroddsen, Tinna-Solveig F","Kehe, Jared","Nguyen, Tien G","Carter, Amber","Kulesa, Anthony","Barnes, John R","Dugan, Vivien G","Hung, Deborah T","Blainey, Paul C","Sabeti, Pardis C"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32349121","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1038/s41586-020-2279-8","topics":["Diagnosis"],"weight":1,"_version_":1666138495461097472,"score":422.42838},{"pmid":32376987,"title":"Inhibition of Influenza A virus propagation by benzoselenoxanthenes stabilizing TMPRSS2 Gene G-quadruplex and hence down-regulating TMPRSS2 expression.","text":["Inhibition of Influenza A virus propagation by benzoselenoxanthenes stabilizing TMPRSS2 Gene G-quadruplex and hence down-regulating TMPRSS2 expression.","Proteolytic cleavage of influenza A virus (IAV) hemagglutinin by host proteases is crucial for virus infectivity and spread. The transmembrane serine protease TMPRSS2 was previously identified as the essential protease that can cleave hemagglutinin of many subtypes of influenza virus and spike protein of coronavirus. Herein, we found that a guanine rich tract, capable of forming intramolecular G-quadruplex in the presence of potassium ions, in the promoter region of human TMPRSS2 gene was quite important for gene transcriptional activity, hence affecting its function. Furthermore, 7 new synthesized benzoselenoxanthene analogues were found to enable stabilizing such G-quadruplex. More importantly, compounds can down-regulate TMPRSS2 gene expression, especially endogenous TMPRSS2 protein levels, and consequently suppress influenza A virus propagation in vitro. Our results provide a new strategy for anti-influenza A virus infection by small molecules targeting the TMPRSS2 gene G-quadruplex and thus inhibiting TMPRSS2 expression, which is valuable for developing small molecule drugs against influenza A virus and also may be a potential candidate as anti- SARS-CoV-2 (Severe Acute Respiratory Syndrome CoV 2) lead molecules.","Sci Rep","Shen, Li-Wen","Qian, Man-Qing","Yu, Kai","Narva, Suresh","Yu, Fei","Wu, Yan-Ling","Zhang, Wen","32376987"],"abstract":["Proteolytic cleavage of influenza A virus (IAV) hemagglutinin by host proteases is crucial for virus infectivity and spread. The transmembrane serine protease TMPRSS2 was previously identified as the essential protease that can cleave hemagglutinin of many subtypes of influenza virus and spike protein of coronavirus. Herein, we found that a guanine rich tract, capable of forming intramolecular G-quadruplex in the presence of potassium ions, in the promoter region of human TMPRSS2 gene was quite important for gene transcriptional activity, hence affecting its function. Furthermore, 7 new synthesized benzoselenoxanthene analogues were found to enable stabilizing such G-quadruplex. More importantly, compounds can down-regulate TMPRSS2 gene expression, especially endogenous TMPRSS2 protein levels, and consequently suppress influenza A virus propagation in vitro. Our results provide a new strategy for anti-influenza A virus infection by small molecules targeting the TMPRSS2 gene G-quadruplex and thus inhibiting TMPRSS2 expression, which is valuable for developing small molecule drugs against influenza A virus and also may be a potential candidate as anti- SARS-CoV-2 (Severe Acute Respiratory Syndrome CoV 2) lead molecules."],"journal":"Sci Rep","authors":["Shen, Li-Wen","Qian, Man-Qing","Yu, Kai","Narva, Suresh","Yu, Fei","Wu, Yan-Ling","Zhang, Wen"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32376987","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1038/s41598-020-64368-8","e_drugs":["Serine","Potassium","Guanine"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666262687698386945,"score":280.73798},{"pmid":32272173,"pmcid":"PMC7194977","title":"Coronavirus membrane fusion mechanism offers a potential target for antiviral development.","text":["Coronavirus membrane fusion mechanism offers a potential target for antiviral development.","The coronavirus disease 2019 (COVID-19) pandemic has focused attention on the need to develop effective therapies against the causative agent, SARS-CoV-2, and also against other pathogenic coronaviruses (CoV) that have emerged in the past or might appear in future. Researchers are therefore focusing on steps in the CoV replication cycle that may be vulnerable to inhibition by broad-spectrum or specific antiviral agents. The conserved nature of the fusion domain and mechanism across the CoV family make it a valuable target to elucidate and develop pan-CoV therapeutics. In this article, we review the role of the CoV spike protein in mediating fusion of the viral and host cell membranes, summarizing the results of research on SARS-CoV, MERS-CoV, and recent peer-reviewed studies of SARS-CoV-2, and suggest that the fusion mechanism be investigated as a potential antiviral target. We also provide a supplemental file containing background information on the biology, epidemiology, and clinical features of all human-infecting coronaviruses, along with a phylogenetic tree of these coronaviruses.","Antiviral Res","Tang, Tiffany","Bidon, Miya","Jaimes, Javier A","Whittaker, Gary R","Daniel, Susan","32272173"],"abstract":["The coronavirus disease 2019 (COVID-19) pandemic has focused attention on the need to develop effective therapies against the causative agent, SARS-CoV-2, and also against other pathogenic coronaviruses (CoV) that have emerged in the past or might appear in future. Researchers are therefore focusing on steps in the CoV replication cycle that may be vulnerable to inhibition by broad-spectrum or specific antiviral agents. The conserved nature of the fusion domain and mechanism across the CoV family make it a valuable target to elucidate and develop pan-CoV therapeutics. In this article, we review the role of the CoV spike protein in mediating fusion of the viral and host cell membranes, summarizing the results of research on SARS-CoV, MERS-CoV, and recent peer-reviewed studies of SARS-CoV-2, and suggest that the fusion mechanism be investigated as a potential antiviral target. We also provide a supplemental file containing background information on the biology, epidemiology, and clinical features of all human-infecting coronaviruses, along with a phylogenetic tree of these coronaviruses."],"journal":"Antiviral Res","authors":["Tang, Tiffany","Bidon, Miya","Jaimes, Javier A","Whittaker, Gary R","Daniel, Susan"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32272173","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.antiviral.2020.104792","keywords":["covid-19","fusion peptide","middle east respiratory syndrome","sars-cov-2","severe acute respiratory syndrome","spike protein"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138491771158528,"score":265.70224},{"pmid":32401064,"title":"CRISPR-Cas Systems Based Molecular Diagnostic Tool for Infectious Diseases and Emerging 2019 Novel Coronavirus (COVID-19) Pneumonia.","text":["CRISPR-Cas Systems Based Molecular Diagnostic Tool for Infectious Diseases and Emerging 2019 Novel Coronavirus (COVID-19) Pneumonia.","Emerging infectious diseases, the persistent potential for destabilizing pandemics, remain a global threat leading to excessive morbidity and mortality. The current outbreak of pneumonia caused by 2019 novel coronavirus (COVID-19) illustrated difficulties in lack of effective drugs for treatment. Accurate and rapid diagnostic tools are essential for early recognition and treatment of infectious diseases, allowing timely implementation of infection control, improved clinical care and other public health measures to stop the spread of the disease. CRISPR-Cas technology speed up the development of infectious disease diagnostics with high rapid and accurate. In this review, we summarize current advance regarding diverse CRISPR-Cas systems, including CRISPR-Cas9, CRISPR-Cas12 and CRISPR-Cas13, in the development of fast, accurate and portable diagnostic tests and highlight the potential of CRISPR-Cas13 in COVID-19 Pneumonia and other emerging infectious diseases diagnosis.","J Drug Target","Xiang, Xiaohong","Qian, Keli","Zhang, Zhen","Lin, Fengyun","Xie, Yang","Liu, Yang","Yang, Zongfa","32401064"],"abstract":["Emerging infectious diseases, the persistent potential for destabilizing pandemics, remain a global threat leading to excessive morbidity and mortality. The current outbreak of pneumonia caused by 2019 novel coronavirus (COVID-19) illustrated difficulties in lack of effective drugs for treatment. Accurate and rapid diagnostic tools are essential for early recognition and treatment of infectious diseases, allowing timely implementation of infection control, improved clinical care and other public health measures to stop the spread of the disease. CRISPR-Cas technology speed up the development of infectious disease diagnostics with high rapid and accurate. In this review, we summarize current advance regarding diverse CRISPR-Cas systems, including CRISPR-Cas9, CRISPR-Cas12 and CRISPR-Cas13, in the development of fast, accurate and portable diagnostic tests and highlight the potential of CRISPR-Cas13 in COVID-19 Pneumonia and other emerging infectious diseases diagnosis."],"journal":"J Drug Target","authors":["Xiang, Xiaohong","Qian, Keli","Zhang, Zhen","Lin, Fengyun","Xie, Yang","Liu, Yang","Yang, Zongfa"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32401064","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1080/1061186X.2020.1769637","keywords":["covid-19","crispr-cas","diagnostics","infectious diseases"],"locations":["Pneumonia"],"topics":["Diagnosis"],"weight":1,"_version_":1666714494696423424,"score":256.6976},{"pmid":32313883,"pmcid":"PMC7170270","title":"Inhaled biguanides and mTOR inhibition for influenza and coronavirus (Review).","text":["Inhaled biguanides and mTOR inhibition for influenza and coronavirus (Review).","The mammalian target of rapamycin (mTOR) signaling pathway senses and responds to nutrient availability, energy sufficiency, stress, hormones and mitogens to modulate protein synthesis. Rapamycin is a bacterial product that can inhibit mTOR via the PI3K/AKT/mTOR pathway. mTOR signaling is necessary for the development of influenza and modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus. In one human study, it was found that the treatment of severe H1N1 influenzarelated pneumonia with rapamycin and steroids improved the outcome. However, in other studies, immunosuppression with systemic steroids, and possibly rapamycin as well, was associated with an increased morbidity/mortality and a prolonged viral replication. In order to avoid the systemic side-effects, some investigators have postulated that the inhalation of rapamycin would be desirable. However, the inhalation of rapamycin, with its well-documented lung toxicity, could be contraindicated. Another class of drug, biguanides, can also inhibit mTOR, but have no lung toxicity. Biguanides are widely used small molecule drugs prescribed as oral anti-diabetics that have exhibited considerable promise in oncology. During the 1971 outbreak of influenza, diabetic patients treated with the biguanides, phenformin and buformin, had a lower incidence of infection than diabetics treated with sulfonylureas or insulin. Both buformin and phenformin reduce the mortality of influenza in mice; phenformin is less effective than buformin. The inhalation of buformin or phenformin for influenza may be an effective novel treatment strategy that would limit the risk of systemic side-effects associated with biguanides due to the low inhaled dose. Coronavirus disease 2019 (COVID-19) is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019-2020 coronavirus outbreak. It is primarily spread between individuals via small droplets emitted from infected individuals when breathing or coughing. PI3K/AKT/mTOR signaling responses play important roles in MERS-CoV infection and may represent a novel drug target for therapeutic intervention strategies. The present review article discusses the effects of biguanides on influenza and coronavirus.","World Acad Sci J","Lehrer, Steven","32313883"],"abstract":["The mammalian target of rapamycin (mTOR) signaling pathway senses and responds to nutrient availability, energy sufficiency, stress, hormones and mitogens to modulate protein synthesis. Rapamycin is a bacterial product that can inhibit mTOR via the PI3K/AKT/mTOR pathway. mTOR signaling is necessary for the development of influenza and modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus. In one human study, it was found that the treatment of severe H1N1 influenzarelated pneumonia with rapamycin and steroids improved the outcome. However, in other studies, immunosuppression with systemic steroids, and possibly rapamycin as well, was associated with an increased morbidity/mortality and a prolonged viral replication. In order to avoid the systemic side-effects, some investigators have postulated that the inhalation of rapamycin would be desirable. However, the inhalation of rapamycin, with its well-documented lung toxicity, could be contraindicated. Another class of drug, biguanides, can also inhibit mTOR, but have no lung toxicity. Biguanides are widely used small molecule drugs prescribed as oral anti-diabetics that have exhibited considerable promise in oncology. During the 1971 outbreak of influenza, diabetic patients treated with the biguanides, phenformin and buformin, had a lower incidence of infection than diabetics treated with sulfonylureas or insulin. Both buformin and phenformin reduce the mortality of influenza in mice; phenformin is less effective than buformin. The inhalation of buformin or phenformin for influenza may be an effective novel treatment strategy that would limit the risk of systemic side-effects associated with biguanides due to the low inhaled dose. Coronavirus disease 2019 (COVID-19) is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019-2020 coronavirus outbreak. It is primarily spread between individuals via small droplets emitted from infected individuals when breathing or coughing. PI3K/AKT/mTOR signaling responses play important roles in MERS-CoV infection and may represent a novel drug target for therapeutic intervention strategies. The present review article discusses the effects of biguanides on influenza and coronavirus."],"journal":"World Acad Sci J","authors":["Lehrer, Steven"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32313883","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.3892/wasj.2020.42","keywords":["biguanides","buformin","influenza","inhaled","mammalian target of rapamycin"],"locations":["Rapamycin","influenza","buformin"],"e_drugs":["Sulfonylurea Compounds","Biguanides","Sirolimus","Buformin","Phenformin","Steroids"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138493524377600,"score":255.45677}]}